StratifAI GmbH
StratifAI is a precision oncology company that develops multimodal AI models to provide prognostic insights from histology images and clinical data, guiding cancer treatment decisions. Their key product, the StratifAI Breast Cancer Recurrence Test, assesses chemotherapy benefits from routine pathology slides, reducing overtreatment and costs compared to genomic assays. They also offer customizable AI biomarker detection tools for biopharma to accelerate drug discovery and clinical trial optimization. Founded in 2023 and spun off from leading universities, StratifAI leverages advanced deep learning and foundation models to improve personalized cancer care and outcomes, targeting oncologists, biopharma, patients, and payers.
StratifAI GmbH
StratifAI is a precision oncology company that develops multimodal AI models to provide prognostic insights from histology images and clinical data, guiding cancer treatment decisions. Their key product, the StratifAI Breast Cancer Recurrence Test, assesses chemotherapy benefits from routine pathology slides, reducing overtreatment and costs compared to genomic assays. They also offer customizable AI biomarker detection tools for biopharma to accelerate drug discovery and clinical trial optimization. Founded in 2023 and spun off from leading universities, StratifAI leverages advanced deep learning and foundation models to improve personalized cancer care and outcomes, targeting oncologists, biopharma, patients, and payers.
